{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:52:25Z","timestamp":1791409945001,"version":"4.3.3"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,8,28]],"date-time":"2027-08-28T00:00:00Z","timestamp":1819411200000},"content-version":"am","delay-in-days":331,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5R01GM122845"],"award-info":[{"award-number":["5R01GM122845"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110432","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:56:35Z","timestamp":1787928995000},"page":"110432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Hybrid design reveals a dopamine D3R ligand with promising in vitro ADME properties"],"prefix":"10.1016","volume":"181","author":[{"given":"Hari K.","family":"Namballa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dorogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip","family":"Patra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Gudipally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne W.","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110432_bb0005","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3389\/fphar.2020.01003","article-title":"Dopamine receptor subtypes, physiology and pharmacology: new ligands and concepts in schizophrenia","volume":"11","author":"Martel","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110432_bb0010","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/pr.110.002642","article-title":"The physiology, signaling, and pharmacology of dopamine receptors","volume":"63","author":"Beaulieu","year":"2011","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110432_bb0015","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1152\/physrev.1998.78.1.189","article-title":"Dopamine receptors: from structure to function","volume":"78","author":"Missale","year":"1998","journal-title":"Physiol. Rev."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110432_bb0020","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/med.21923","article-title":"Recent advances in dopamine D(2) receptor ligands in the treatment of neuropsychiatric disorders","volume":"43","author":"Juza","year":"2023","journal-title":"Med. Res. Rev."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110432_bb0025","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/13543776.2022.2049240","article-title":"Dopamine D3 receptor ligands: a patent review (2014-2020)","volume":"32","author":"Di Martino","year":"2022","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2026.110432_bb0030","article-title":"The signaling and pharmacology of the dopamine D1 receptor","volume":"15","author":"Jones-Tabah","year":"2021","journal-title":"Front. Cell. Neurosci."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110432_bb0035","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/med.20130","article-title":"Dopamine D1 receptor ligands: where are we now and where are we going","volume":"29","author":"Zhang","year":"2009","journal-title":"Med. Res. Rev."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110432_bb0040","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.clinthera.2006.08.004","article-title":"A review of the receptor-binding and pharmacokinetic properties of dopamine agonists","volume":"28","author":"Kvernmo","year":"2006","journal-title":"Clin. Ther."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110432_bb0045","doi-asserted-by":"crossref","first-page":"5526","DOI":"10.1021\/acs.jmedchem.0c00424","article-title":"Discovery, optimization, and characterization of ML417: a novel and highly selective D(3) dopamine receptor agonist","volume":"63","author":"Moritz","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110432_bb0050","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cellsig.2017.07.003","article-title":"Advances and challenges in the search for D(2) and D(3) dopamine receptor-selective compounds","volume":"41","author":"Moritz","year":"2018","journal-title":"Cell. Signal."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110432_bb0055","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1039\/C8MD00237A","article-title":"Design, synthesis, and evaluation of bitopic arylpiperazine-phthalimides as selective dopamine D(3) receptor agonists","volume":"9","author":"Cao","year":"2018","journal-title":"Medchemcomm"},{"issue":"21","key":"10.1016\/j.bioorg.2026.110432_bb0060","doi-asserted-by":"crossref","first-page":"16088","DOI":"10.1021\/acs.jmedchem.1c01433","article-title":"Chiral cyclic aliphatic linkers as building blocks for selective dopamine D(2) or D(3) receptor agonists","volume":"64","author":"Battiti","year":"2021","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110432_bb0065","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1124\/jpet.121.000701","article-title":"Effects of dopamine D1-like receptor ligands on food-cocaine choice in socially housed male Cynomolgus monkeys","volume":"379","author":"Czoty","year":"2021","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3\u20134","key":"10.1016\/j.bioorg.2026.110432_bb0070","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00213-002-1137-8","article-title":"Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development","volume":"163","author":"Platt","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110432_bb0075","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s002130100779","article-title":"Modulation of cocaine and food self-administration by low- and high-efficacy D1 agonists in squirrel monkeys","volume":"157","author":"Platt","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"issue":"20","key":"10.1016\/j.bioorg.2026.110432_bb0080","doi-asserted-by":"crossref","first-page":"4796","DOI":"10.1111\/bph.15244","article-title":"(+\/\u2212)VK4-40, a novel dopamine D(3) receptor partial agonist, attenuates cocaine reward and relapse in rodents","volume":"177","author":"Jordan","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110432_bb0085","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.neuropharm.2013.10.010","article-title":"Blockade of D3 receptors by YQA14 inhibits cocaine's rewarding effects and relapse to drug-seeking behavior in rats","volume":"77","author":"Song","year":"2014","journal-title":"Neuropharmacology"},{"issue":"8","key":"10.1016\/j.bioorg.2026.110432_bb0090","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.neuropharm.2012.08.011","article-title":"Phenylpiperazine derivatives with selectivity for dopamine D3 receptors modulate cocaine self-administration in rats","volume":"63","author":"Cheung","year":"2012","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.1016\/j.bioorg.2026.110432_bb0095","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.bcp.2012.06.023","article-title":"Medication discovery for addiction: translating the dopamine D3 receptor hypothesis","volume":"84","author":"Newman","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110432_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2024.112494","article-title":"Selective dopamine D3 receptor partial agonist (+\/\u2212)VK4-40 reduces the reinforcing strength of d-amphetamine but not cocaine in rhesus monkeys responding under a progressive-ratio schedule of reinforcement","volume":"265","author":"Allen","year":"2024","journal-title":"Drug Alcohol Depend."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110432_bb0105","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1038\/s41386-024-01858-7","article-title":"The selective D(3)receptor antagonist VK4-116 reverses loss of insight caused by self-administration of cocaine in rats","volume":"49","author":"Panayi","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bioorg.2026.110432_bb0110","article-title":"The selective D3-receptor antagonist VK4\u2013116 effectively treats behavioral inflexibility in rats caused by self-administration and withdrawal from cocaine","author":"Panayi","year":"2023","journal-title":"bioRxiv"},{"issue":"8","key":"10.1016\/j.bioorg.2026.110432_bb0115","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41386-018-0284-5","article-title":"Dopamine D(3)R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects","volume":"44","author":"You","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bioorg.2026.110432_bb0120","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3389\/fnins.2016.00451","article-title":"Dopamine D3 receptor antagonists as potential therapeutics for the treatment of neurological diseases","volume":"10","author":"Maramai","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.bioorg.2026.110432_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128047","article-title":"New tetrahydroisoquinoline-based D(3)R ligands with an o-xylenyl linker motif","volume":"42","author":"Cordone","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110432_bb0130","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1021\/acs.jmedchem.6b01688","article-title":"Synthesis and pharmacological characterization of novel trans-Cyclopropylmethyl-linked bivalent ligands that exhibit selectivity and allosteric pharmacology at the dopamine D(3) receptor (D(3)R)","volume":"60","author":"Kumar","year":"2017","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.bioorg.2026.110432_bb0135","doi-asserted-by":"crossref","first-page":"6689","DOI":"10.1021\/jm300482h","article-title":"Molecular determinants of selectivity and efficacy at the dopamine D3 receptor","volume":"55","author":"Newman","year":"2012","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110432_bb0140","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/s41467-017-02776-7","article-title":"Impaired beta-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor","volume":"9","author":"Gray","year":"2018","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110432_bb0145","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1021\/acs.jmedchem.9b00351","article-title":"Defining structure-functional selectivity relationships (SFSR) for a class of non-catechol dopamine D(1) receptor agonists","volume":"62","author":"Martini","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110432_bb0150","article-title":"Functionally selective dopamine D1 receptor endocytosis and signaling by catechol and non-catechol agonists","author":"Nilson","year":"2024","journal-title":"bioRxiv"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110432_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.112345","article-title":"Characterization of Galpha(s) and Galpha(olf) activation by catechol and non-catechol dopamine D1 receptor agonists","volume":"28","author":"Nguyen","year":"2025","journal-title":"iScience"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110432_bb0160","doi-asserted-by":"crossref","first-page":"476","DOI":"10.2174\/1871527322666230331121028","article-title":"Rationale and development of Tavapadon, a D1\/D5-selective partial dopamine agonist for the treatment of Parkinson\u2019s disease","volume":"23","author":"Bezard","year":"2024","journal-title":"CNS Neurol. Disord. Drug Targets"},{"issue":"9","key":"10.1016\/j.bioorg.2026.110432_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/diseases13090290","article-title":"Emerging clinical role of Tavapadon, a novel dopamine partial agonist, in the treatment of Parkinson\u2019s disease","volume":"13","author":"Kaye","year":"2025","journal-title":"Diseases"},{"issue":"9","key":"10.1016\/j.bioorg.2026.110432_bb0170","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","article-title":"pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures","volume":"58","author":"Pires","year":"2015","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110432_bb0175","doi-asserted-by":"crossref","first-page":"7759","DOI":"10.1038\/s41467-024-51993-4","article-title":"A bitopic agonist bound to the dopamine 3 receptor reveals a selectivity site","volume":"15","author":"Arroyo-Urea","year":"2024","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110432_bb0180","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826009685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826009685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:20:27Z","timestamp":1791408027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826009685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":36,"alternative-id":["S0045206826009685"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110432","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hybrid design reveals a dopamine D3R ligand with promising in vitro ADME properties","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110432","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110432"}}